First approval for Kyowa Kirin's lead biologic, for ATL in Japan
This article was originally published in Scrip
Kyowa Hakko Kirin has received the first approval worldwide for its lead therapeutic biologic, in Japan for the chemokine [C-C motif] receptor 4-targeting antibody Poteligeo (mogamulizumab; KW-0761).
You may also be interested in...
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.